Compare Vertex Pharmaceuticals Incorporated (VRTX) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs WD 40 Company — how do they compare? Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B), while WD 40 Company trades at $237.72 (market cap $3.22B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 37.9× WD 40 Company's market cap, and WD 40 Company pays a 1.7% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | WDFC | |
|---|---|---|
Market Cap | $121.95B | $3.22B |
Sector | Health | Technology |
52-Week High | $529.59 | $264.91 |
52-Week Low | $366.54 | $187.52 |
Enterprise Value | $116.69B | $3.27B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
WDFC trades at $239.59, down 2.92% today, with a bullish technical signal supported by moving averages and ADX indicators. Recent Q2 2026 earnings beat expectations at $2.33 EPS versus $1.58 expected, driven by strong sales growth. The company maintains solid profitability with a 13.22% net income margin and positive operating cash flow of $87.93 million in 2025, though 2026 projections show slight margin compression.
The outlook is mixed: strong brand moat and consistent cash flow support dividends, but high valuation multiples (P/E 37.5) and analyst caution (71% hold rating) limit near-term upside. Risks include input cost pressures and competitive maintenance markets. Institutional sentiment leans neutral despite recent earnings strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
